StocksFundsScreenerSectorsWatchlists
MTNB

MTNB - Matinas BioPharma Holdings Inc Stock Price, Fair Value and News

0.29USD0.00 (0.00%)Market Closed

Market Summary

MTNB
USD0.290.00
Market Closed
0.00%

MTNB Stock Price

View Fullscreen

MTNB RSI Chart

MTNB Valuation

Market Cap

60.8M

Price/Earnings (Trailing)

-2.65

Price/Sales (Trailing)

55.51

Price/Free Cashflow

-3.93

MTNB Price/Sales (Trailing)

MTNB Profitability

Return on Equity

-119.2%

Return on Assets

-91.39%

Free Cashflow Yield

-25.47%

MTNB Fundamentals

MTNB Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

MTNB Earnings

Earnings (TTM)

-22.9M

Earnings Growth (Yr)

-46.23%

Earnings Growth (Qtr)

12.24%

Breaking Down MTNB Revenue

Last 7 days

-6.7%

Last 30 days

21.7%

Last 90 days

27.3%

Trailing 12 Months

-28.0%

How does MTNB drawdown profile look like?

MTNB Financial Health

Current Ratio

5.93

MTNB Investor Care

Diluted EPS (TTM)

-0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.3M3.2M2.2M1.1M
202202.3M2.7M3.2M
2021483.7K934.4K1.4M1.8M
20200061.4K33.0K
20190179.6K89.8K89.8K
2018164.7K209.6K164.7K119.8K
2017151.8K119.7K104.8K149.7K
2015000194.5K

Tracking the Latest Insider Buys and Sells of Matinas BioPharma Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 22, 2022
conrad herbert j
gifted
-
-
1,358,120
-
Jun 22, 2022
conrad herbert j
gifted
-
-
-1,358,120
-
Dec 31, 2021
wikler matthew
acquired
-
-
7,859
-
Sep 30, 2021
wikler matthew
acquired
-
-
6,106
-
Sep 03, 2021
mannino raphael j
acquired
-
-
462,150
chief scientific officer
Aug 04, 2021
conrad herbert j
gifted
-
-
494,622
-
Aug 04, 2021
conrad herbert j
gifted
-
-
-494,622
-
Jul 07, 2021
conrad herbert j
gifted
-
-
-1,280,920
-
Jul 07, 2021
conrad herbert j
gifted
-
-
1,280,920
-
Jun 30, 2021
wikler matthew
acquired
-
-
10,244
-

1–10 of 50

Which funds bought or sold MTNB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
6.44
876,521
2,014,520
-%
Feb 26, 2024
Virtu Financial LLC
new
-
35,000
35,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-4,485
-
-%
Feb 14, 2024
Bayesian Capital Management, LP
new
-
4,065
4,065
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
4,127
4,127
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
2,974
2,974
-%
Feb 14, 2024
LPL Financial LLC
reduced
-0.65
52,366
132,645
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
8,318
20,863
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-3.58
1,000
2,000
-%

1–10 of 50

Are Funds Buying or Selling MTNB?

Are funds buying MTNB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MTNB
No. of Funds

Unveiling Matinas BioPharma Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2022
boxer capital, llc
0.0%
0
SC 13G/A
Feb 16, 2021
boxer capital, llc
5.8%
11,478,634
SC 13G/A
Feb 12, 2021
vivo capital ix, llc
0.6%
1,176,974
SC 13G/A
Feb 14, 2020
boxer capital, llc
6.3%
10,188,312
SC 13G/A
Feb 13, 2020
vivo capital ix, llc
0.9%
1,826,015
SC 13G/A

Recent SEC filings of Matinas BioPharma Holdings Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
8-K
Current Report
Mar 27, 2024
10-K
Annual Report
Mar 25, 2024
8-K
Current Report
Mar 22, 2024
8-K
Current Report
Mar 22, 2024
8-K
Current Report
Feb 26, 2024
8-K
Current Report
Feb 20, 2024
8-K
Current Report
Jan 09, 2024
8-K
Current Report
Dec 27, 2023
8-K
Current Report
Dec 21, 2023
8-K
Current Report

Peers (Alternatives to Matinas BioPharma Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Matinas BioPharma Holdings Inc News

Latest updates
Yahoo Finance • 22 Mar 2024 • 04:37 pm
MarketBeat • 12 Mar 2024 • 11:40 am
Penny Stocks • 4 months ago

Matinas BioPharma Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22021Q42021Q32021Q22021Q12020Q42020Q32019Q42019Q42019Q32019Q22018Q42018Q32018Q22018Q1
Revenue----1,0961,0631,0631,063532--33.0065.0096.0064.0032.00-90.00--90.0030.00
Costs and Expenses-4.0%5,8876,1346,1596,6826,5436,5256,9886,7146,8784,7906,3866,5515,7005,736-4,5614,6104,1672,9543,4954,151
  S&GA Expenses-21.7%2,2222,8392,6002,7122,6772,8182,8612,4742,2572,3093,1453,0262,3642,316-1,8901,7822,4741,5751,9721,958
  R&D Expenses11.2%3,6653,2953,5593,9703,8673,7074,1274,2404,6212,4813,2413,5263,3363,420-2,6712,8291,6921,3801,523-
Net Income12.2%-5,314-6,055-6,060-5,513-3,634-5,462-5,923-6,699-6,836-4,791-4,956-6,340-5,449-5,572--4,404-3,344-3,626-2,935-3,411-4,110
Net Income Margin-112.6%-20.93*-9.85*-6.41*-4.79*-6.59*-8.79*-11.12*-12.68*-16.55*-23.05*-46.22*-680.21*---------
Free Cashflow-3.2%-4,579-4,435-2,235-4,129-4,341-5,220-5,186-3,993-5,973-864-4,650-4,307---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-15.7%25.0030.0034.0038.0045.0048.0052.0056.0061.0067.0070.0072.0071.0075.0079.0084.0040.0045.0048.0051.0020.00
  Current Assets-22.2%16.0020.0024.0028.0035.0037.0042.0045.0051.0056.0061.0063.0062.0065.0069.0074.0030.0034.0037.0040.0013.00
    Cash Equivalents-25.3%5.006.0010.006.007.0011.0010.0019.0021.0025.0030.0023.0012.007.0015.0010.0022.0033.0037.0039.0012.00
  Net PPE-4.8%2.002.002.002.002.002.002.002.002.002.001.001.002.002.002.002.002.002.002.002.002.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities-11.8%6.007.006.006.008.009.0010.008.009.009.007.006.007.007.006.007.007.007.008.008.004.00
  Current Liabilities-18.8%3.003.003.002.004.005.005.004.004.004.004.002.004.003.002.003.003.003.003.003.003.00
Shareholder's Equity-16.9%19.0023.0028.0033.0037.0039.0043.0048.0052.0058.0063.0067.0064.0068.0073.0078.0033.0038.0040.0043.0016.00
  Retained Earnings-3.1%-175-170-164-158-152-149-143-137-131-124-118-112-107-101-95.72-89.42-84.38-78.80-73.81-70.00-65.94
  Additional Paid-In Capital0.7%19519419319119018918718618418318117516716516416311311310510372.00
Shares Outstanding0%217217217217217217217217216208205204---------
Float-------165---160---142---112--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-3.6%-4,579-4,419-2,193-4,087-4,299-4,970-5,131-4,756-3,957-5,749-864-4,651-4,307-5,226-3,168-4,664-4,898-4,073-2,096-3,023-2,619
  Share Based Compensation6.4%1,2721,1961,2081,2721,3401,4131,2151,2601,0741,0611,0561,1011,2209539451,4476886718228041,030
Cashflow From Investing173.1%2,9601,0846,1983,000-42.005,750-3,7922,96157.002437,6548,8179,089-2,7807,991-54,967-5,605-73.43-317-14.25-
Cashflow From Financing0%-1.00-1.00-1.00-4.00-5.00-3.00-6.0093.008.00-8.321806,78555054.004.0047,43910.00-19.53-16730,0288,359

MTNB Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Contract Revenue$ 1,063$ 1,096$ 2,125
Costs and expenses:    
Research and development3,2953,70710,82412,811
General and administrative2,8392,8188,1518,424
Total costs and expenses6,1346,52518,97521,235
Loss from operations(6,134)(5,462)(17,879)(19,110)
Sale of New Jersey net operating losses & tax credits1,734
Other income, net7925113
Net loss$ (6,055)$ (5,462)$ (17,628)$ (17,363)
Net loss per share - basic$ (0.03)$ (0.03)$ (0.08)$ (0.08)
Net loss per share - diluted$ (0.03)$ (0.03)$ (0.08)$ (0.08)
Weighted average common shares outstanding:    
Weighted average common shares outstanding - basic217,264,526216,864,526217,264,526216,792,083
Weighted average common shares outstanding - diluted217,264,526216,864,526217,264,526216,792,083
Other comprehensive gain/(loss), net of tax    
Unrealized gain/(loss) on securities available-for-sale$ 155$ (181)$ 465$ (790)
Other comprehensive gain/(loss), net of tax155(181)465(790)
Comprehensive loss$ (5,900)$ (5,643)$ (17,163)$ (18,153)

MTNB Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 6,407$ 6,830
Marketable debt securities11,80921,933
Restricted cash – security deposit5050
Prepaid expenses and other current assets1,7235,719
Total current assets19,98934,532
Non-current assets:  
Leasehold improvements and equipment – net2,0212,091
Operating lease right-of-use assets – net3,2063,613
Finance lease right-of-use assets – net2230
In-process research and development3,0173,017
Goodwill1,3361,336
Restricted cash – security deposit200200
Total non-current assets9,80210,287
Total assets29,79144,819
Current liabilities:  
Accounts payable835618
Accrued expenses1,7573,099
Operating lease liabilities – current632562
Financing lease liabilities – current57
Total current liabilities3,2294,286
Non-current liabilities:  
Deferred tax liability341341
Operating lease liabilities – net of current portion3,0523,533
Financing lease liabilities – net of current portion1922
Total non-current liabilities3,4123,896
Total liabilities6,6418,182
Stockholders’ equity:  
Common stock par value $0.0001 per share, 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 217,264,526 issued and outstanding as of September 30, 2023 and December 31, 20222222
Additional paid-in capital193,746190,070
Accumulated deficit(170,259)(152,631)
Accumulated other comprehensive loss(359)(824)
Total stockholders’ equity23,15036,637
Total liabilities and stockholders’ equity$ 29,791$ 44,819
MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
 CEO
 WEBSITEwww.matinasbiopharma.com
 EMPLOYEES34

Matinas BioPharma Holdings Inc Frequently Asked Questions


What is the ticker symbol for Matinas BioPharma Holdings Inc? What does MTNB stand for in stocks?

MTNB is the stock ticker symbol of Matinas BioPharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Matinas BioPharma Holdings Inc (MTNB)?

As of Wed Mar 27 2024, market cap of Matinas BioPharma Holdings Inc is 63.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTNB stock?

You can check MTNB's fair value in chart for subscribers.

What is the fair value of MTNB stock?

You can check MTNB's fair value in chart for subscribers. The fair value of Matinas BioPharma Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Matinas BioPharma Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MTNB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Matinas BioPharma Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MTNB is over valued or under valued. Whether Matinas BioPharma Holdings Inc is cheap or expensive depends on the assumptions which impact Matinas BioPharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTNB.

What is Matinas BioPharma Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, MTNB's PE ratio (Price to Earnings) is -2.96 and Price to Sales (PS) ratio is 29.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTNB PE ratio will change depending on the future growth rate expectations of investors.